Hemay005 clinical trials
Also written Hemay005.
How each study uses Hemay005 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Hemay005 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 5 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 20 · Other 0
Ganzhou Hemay Pharmaceutical Co., Ltd (11) · Tianjin Hemay Pharmaceutical Co., Ltd (5) · Tianjin Hemay Bio-Tech Co., Ltd (3) · Anhui Hemay Pharmaceutical Co., Ltd (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Hemay005.
- Dec 2026Phase II Study of Hemay005 in Patients With Active Ulcerative ColitisPhase 2 · Ganzhou Hemay Pharmaceutical Co., Ltd
Studies
Open first, then newest update. How each study uses Hemay005 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 20
- Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative ColitisNot yet recruitingPhase 3Ganzhou Hemay Pharmaceutical Co., LtdNCT07650942Written as Hemay005 tablet
- A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPDNot yet recruitingPhase 2Ganzhou Hemay Pharmaceutical Co., LtdNCT07314242Written as Hemay005 tablets
- To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver DamageRecruitingPhase 1Ganzhou Hemay Pharmaceutical Co., LtdNCT06376474Written as Hemay005
- A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingPhase 3Ganzhou Hemay Pharmaceutical Co., LtdNCT06145893Written as Hemay005
- Phase II Study of Hemay005 in Patients With Active Ulcerative ColitisActive, not recruitingPhase 2Ganzhou Hemay Pharmaceutical Co., LtdNCT05486104Written as Hemay005 tablets
- Evaluation the Safety of hemay005 TabletsCompletedPhase 1Anhui Hemay Pharmaceutical Co., LtdNCT06908642Written as Hemay005 tablet
- To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal ImpairmentCompletedPhase 1Ganzhou Hemay Pharmaceutical Co., LtdNCT06380153Written as Hemay005
- Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate TabletsCompletedPhase 1Ganzhou Hemay Pharmaceutical Co., LtdNCT06610890Written as Hemay005
- Bioequivalence Test of Hemay005 TabletsCompletedPhase 1Ganzhou Hemay Pharmaceutical Co., LtdNCT06610903Written as Hemay005
- Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy SubjectsCompletedPhase 1Tianjin Hemay Pharmaceutical Co., LtdNCT04837235Written as Hemay005
- A Study of Hemay005 in Adult With Atopic DermatitisCompletedPhase 2Ganzhou Hemay Pharmaceutical Co., LtdNCT05769946Written as Hemay005
- A Study to Evaluate the Effects of Single and Multiple Doses of Hemay005 Tablets in Health Caucasian Adult VolunteersCompletedPhase 1Ganzhou Hemay Pharmaceutical Co., LtdNCT05941247Written as Hemay005 60 mg
- In Vivo Mass Balance Study of [14C]Hemay005CompletedPhase 1Ganzhou Hemay Pharmaceutical Co., LtdNCT05468645Written as [14C]Hemay005
- A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque PsoriasisCompletedPhase 3Tianjin Hemay Pharmaceutical Co., LtdNCT04839328Written as 60mg Hemay005
- Phase II Study of Hemay005 in Patients With Active Ankylosing SpondylitisCompletedPhase 2Tianjin Hemay Pharmaceutical Co., LtdNCT05407246Written as Hemay005
- A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedPhase 2Tianjin Hemay Pharmaceutical Co., LtdNCT04609397Written as Hemay005
- Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque PsoriasisCompletedPhase 2Tianjin Hemay Pharmaceutical Co., LtdNCT04102241Written as 15mg Hemay005
- Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy SubjectsStatus unknownPhase 1Tianjin Hemay Bio-Tech Co., LtdNCT03570346Written as Hemay005
- A Food Effect Study to Assess Pharmacokinetics of Hemay005 in Healthy VolunteersStatus unknownPhase 1Tianjin Hemay Bio-Tech Co., LtdNCT03577626Written as Hemay005
- Safety and Pharmacokinetics of Hemay005 In Healthy Male SubjectsCompletedPhase 1Tianjin Hemay Bio-Tech Co., LtdNCT03007810Written as Hemay005
Codes
What other systems call Hemay005 · ClinicalTrials.gg INT000995
- MeSH (NLM) C000628605Hemay005One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628605 | Hemay005 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.